The landscape of dementia prognosis has evolved considerably with the advent of refined biomarkers, which include amyloid PET scans, tau imaging, and blood-based tests that will detect Alzheimer's pathology several years right before symptoms emerge. Whilst these technological advances symbolize remarkable progress in comprehending neurodegenerativ